AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of Common Shares Worth $3,166.644

PUBT · 2d ago
AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of Common Shares Worth $3,166.644
  • AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 20,299 shares of Common Stock.
  • The purchase price was $0.156 per share, bringing his direct holdings to 210,046 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050412), on November 06, 2026, and is solely responsible for the information contained therein.